




Applied Genetic Technologies Corporation  
Investor Relations Department  
14193 NW 119th Terrace  
Suite 10  
Alachua, FL 32615  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

#### NASDAQ: AGTC

|               |  |
|---------------|--|
| Last Trade:   | 4.75   |
| Trade Time:   | 4:00 PM ET<br>Jul 27, 2017   |
| Change:       | -0.35  (6.863%) |
| Day Range     | 4.75 - 5.10  |
| 52-Week Range | 4.60 - 17.00   |
| Volume        | 79,160   |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates focus on inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked r... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jun 15, 2017*

[IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia](#)

*Jun 8, 2017*

[AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study](#)

*Jun 8, 2017*

[Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Investigational Gene-Based Therapy for Alpha-1 Antitrypsin \(AAT\) Deficiency](#)

*May 11, 2017*

[AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting](#)

*May 10, 2017*

[AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017](#)

### Financials [\[ View all \]](#)

*Sep 12, 2016*

[Annual Report \(10-K\)](#)

*Jan 13, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)

*Feb 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)